Danaher Guides Q3 Core Revenue Growth to 2%-3%, Shares Drop 15%
DHR is trading near its 52-week low of $160.93 (6.8% above the low).
Summary
Danaher reported a strong Q2 beat but guided Q3 core revenue growth to just 2%-3%, well below the 5.5% growth just posted, citing customer-project timing in bioprocessing. The stock plunged 15% premarket. Full-year EPS guidance was raised slightly to $8.45-$8.60, but the improvement is largely from the earlier-than-expected Masimo acquisition close, not organic strength. Interest expense jumped to $107M from $71M as debt doubled to fund the deal. Bioprocessing orders grew mid-teens, and management expects to exit 2026 at mid-single-digit core growth, but the near-term slowdown is a sharp reset. This follows the Q2 beat reported earlier today, adding the crucial guidance and market reaction.
At the time of this announcement, DHR was trading at $171.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $142.3B. The 52-week trading range was $160.93 to $242.80. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.